Drug discovery and development

The charity’s commercial arm saw the amount of money from both internal and external sources invested in its spinouts more than double in the last year.

The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours.

Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back.

Scientists are developing a new drug for treating acute myeloid leukaemia (AML), a type of blood cancer that affects around 3,100 people in the UK each year. 

Researchers in Cambridge have pioneered the development of an innovative affinity maturation technique to generate high-affinity antibody against Arginase 2.

Cancer Research UK and VOLT, announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer

Researchers have demonstrated an approach which, used in parallel with existing treatments, wipes out the ‘survival system’ of cancer cells.

A clinical trial testing a new treatment combination in patients with leukaemia launches through the Combinations Alliance today.

Cancer Research UK and The Institute of Cancer Research, London announce a multi-project collaboration and licensing deal with Merck.

Cancer Research UK announces the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology, and Celgene Corporation